BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Optimizing Care in Myasthenia Gravis (MG)

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Wednesday, May 18, 2022

Faculty

Neelam Goyal, MD
Clinical Associate Professor, Neurology & Neurological Sciences
Stanford University, CA
Gil I. Wolfe, MD, FAAN
Irvin and Rosemary Smith Professor and Chair, Department of Neurology
University at Buffalo Jacobs School of Medicine and Biomedical Sciences/SUNY
Claire Spahn, PharmD, BCPS
Clinical Pharmacist, Neuroscience
Stanford University, CA
Karen Kurdziel, MD
Patient Perspective
On-Demand
Activity Overview: 

This webinar featuring Dr. Neelam Goyal, Dr. Clair Spahn, Dr. Gil Wolfe and Dr. Karen Kurdziel, discusses the use of a multidisciplinary team approach to provide the best care to patients with myasthenia gravis (MG). This webinar includes the review of signs and symptoms of MG, best practice guidelines, and available therapies and clinical trial opportunities.

Learning Objectives: 
  • Recognize MG signs and symptoms, and know when to consult with specialists
  • Understand how to manage MG according to best practice guidelines
  • Understand the optimal multidisciplinary team design for MG management
  • Identify facilitating factors and hurdles to building a multidisciplinary care team or importing outside expertise to help manage patients with MG
  • Identify and obtain telemedicine tools that would allow connection with multidisciplinary treatment centers Inform patients of available therapies and clinical trial opportunities
Accreditation and Designation Statement: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the Muscular Dystrophy Association. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Enduring activity dates: May 2, 2022 – May 1, 2025

How to Obtain CME credits : 

Once you have viewed the program, MDA will share back with you instructions for how to obtain your CME credits. If you have questions on this process, please reach out to cmemanagement@mdausa.org.

Faculty Disclosures: 

The following presenters, planners, editors, or staff have relevant financial relationships to disclose:

“I, have at present or have had within the last 12 months, the following affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation or evaluation of CME Activities.”

Neelam Goyal, MD

Alexion: Advisory committee, teaching; consulting fee

Argenx: Advisory committee, speaking/teaching; consulting fee

UCB: Advisory committee; consulting fee

Gil I. Wolfe, MD, FAAN

Alexion: Consulting, speaking; consulting fees, honoraria

UCB: Clinical trials, consulting; consulting fees, research

Grifols: Consulting, speaking; consulting fees, honoraria

CSL: Consulting; consulting fees

ArgenX: Clinical trials, consulting; Consulting fees, research

Immunovant: Clinical trials; research

The above disclosure of financial relationships with ineligible companies has been mitigated by PeerPoint Medical Education Institute and the Muscular Dystrophy Association.

All other presenters, planners, editors, or staff report no relevant disclosure relationships:

“I do not have at present, or within the last 12 months, nor anticipate having financial interest, arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation or evaluationof CME Activities"